These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8548117)

  • 1. Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control.
    Antman EM
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):962-71. PubMed ID: 8548117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintaining sinus rhythm with antifibrillatory drugs in atrial fibrillation.
    Antman EM
    Am J Cardiol; 1996 Aug; 78(4A):67-72. PubMed ID: 8780331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation.
    Hagens VE; Van Gelder IC; Crijns HJ;
    Card Electrophysiol Rev; 2003 Jun; 7(2):118-21. PubMed ID: 14618033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation: antiarrhythmic therapy versus rate control with antithrombotic therapy.
    Sager PT
    Am J Cardiol; 1997 Oct; 80(8A):74G-81G. PubMed ID: 9354414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacologic maintenance of sinusal rhythm and/or control of the ventricular response in patients with atrial fibrillation or flutter].
    López Gil M; Arribas F; Hernández Afonso J; Angel Santos M; García-Cosío F
    Rev Esp Cardiol; 1996; 49 Suppl 2():32-41. PubMed ID: 8755694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate versus rhythm control in atrial fibrillation.
    Wijffels MC; Crijns HJ
    Cardiol Clin; 2004 Feb; 22(1):63-9. PubMed ID: 14994848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of rate control versus maintenance of sinus rhythm.
    Saxonhouse SJ; Curtis AB
    Am J Cardiol; 2003 Mar; 91(6A):27D-32D. PubMed ID: 12670639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
    Van Gelder IC; Crijns HJ; Van Gilst WH; Van Wijk LM; Hamer HP; Lie KI
    Am J Cardiol; 1989 Dec; 64(19):1317-21. PubMed ID: 2511744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say.
    Crijns HJ
    Drugs; 2005; 65(12):1651-67. PubMed ID: 16060699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of antiarrhythmic drug therapy after DC electrical cardioversion of atrial fibrillation or flutter.
    Crijns HJ; van Gelder IC; Lie KI
    Eur Heart J; 1994 Apr; 15 Suppl A():17-21. PubMed ID: 8070491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confounding factors in rate versus rhythm control trials in patients with atrial fibrillation: lessons from the strategies of treatment of atrial fibrillation (STAF) pilot study.
    Carlsson J; Boos C
    Card Electrophysiol Rev; 2003 Jun; 7(2):122-6. PubMed ID: 14618034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological management of atrial fibrillation: an update.
    Hohnloser SH; Li YG; Bender B; Grönefeld G
    J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):11-6. PubMed ID: 10687669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
    Benditt DG; Williams JH; Jin J; Deering TF; Zucker R; Browne K; Chang-Sing P; Singh BN
    Am J Cardiol; 1999 Aug; 84(3):270-7. PubMed ID: 10496434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial.
    Hohnloser SH; Kuck KH
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 1):1989-92. PubMed ID: 9272538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of atrial fibrillation and atrial flutter: Part II.
    Aronow WS
    Cardiol Rev; 2008; 16(5):230-9. PubMed ID: 18708824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN; Mody FV; Lopez B; Sarma JS
    Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial flutter, atrial fibrillation, and other primary atrial tachycardias.
    Benditt DG; Benson DW; Dunnigan A; Gornick CC; Anderson RW
    Med Clin North Am; 1984 Jul; 68(4):895-918. PubMed ID: 6381928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
    Singh BN; Connolly SJ; Crijns HJ; Roy D; Kowey PR; Capucci A; Radzik D; Aliot EM; Hohnloser SH;
    N Engl J Med; 2007 Sep; 357(10):987-99. PubMed ID: 17804843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some recent randomized clinical trials in the management of atrial fibrillation.
    Wyse DG
    J Interv Card Electrophysiol; 2003 Oct; 9(2):223-8. PubMed ID: 14574035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.